Allergy is a significant component in many asthma patients. Omalizumab is a monoclonal anti–immunoglobulin E antibody for the treatment of allergic asthma. Clinical trials have shown that omalizumab treatment is associated with improved symptom control and reduced inhaled corticosteroid doses, resulting in fewer exacerbations and reduced utilization of resources. Omalizumab therapy may benefit patients who remain uncontrolled or who cannot tolerate standard therapy.
Key words: adult, asthma, immunoglobulin E, monoclonal antibody, prior authorization
Jill Karpel, MD
410 Lakeville Road, Suite 107
New Hyde Park, N.Y. 11040
Fax: 516 465-5454